Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 3NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 17Other hematologic neoplasm 14Sarcoma 5CNS 5Breast 5Gynecologic 3Myeloid 2Thoracic 1Plasma cell 1Head & Neck 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Adenocarcinoma, Bronchiolo-Alveolar 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 71Carboplatin 68Paclitaxel 57Radiotherapy 43Specimen Handling 37Gemcitabine 36Erlotinib Hydrochloride 32Etoposide 30Magnetic Resonance Spectroscopy 29Docetaxel 28Taxes 27Pemetrexed 23Platinum 20Vinorelbine 191,2-diaminocyclohexaneplatinum II citrate 19Bevacizumab 18Cyclophosphamide 16Biopsy 16Radiation 15pembrolizumab 14Immunoglobulin G 12Disulfides 12Topotecan 11Gefitinib 11durvalumab 9atezolizumab 9aldesleukin 9Nivolumab 9Irinotecan 9Bortezomib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Granulocyte Colony-Stimulating Factor × Thoracic × Clear all
NCT00334815 2026-05-26

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
29 enrolled 10 charts
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Bronchiolo-Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡